Which of these was your favorite Super Bowl commercial?
We thought we’d take a break from serious healthcare topics this week and ask a just-for-fun question about Super Bowl ad preferences. We saw Pfizer's "Here's To Science." but as far as we know, no other healthcare companies advertised during last night’s game, which the Kansas City Chiefs won in overtime, much to the delight of a certain singer and her boyfriend. For lack of a big showing by healthcare companies, we selected some advertisers that are somewhat health and healthcare adjacent. And we added a couple of our favorites (those E*Trade babies get us every time).
What was your favorite Superbowl commercial?
We want to know what you’re thinking! Every Monday morning, the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. We'll tally your answers and publish the results on Friday by 4 p.m. ET.
Have a suggestion for a Question for the Week? Please send it to Peter Wehrwein at pwehrwein@mjhlifesciences.com
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More